Becton Dickinson & Co (NYSE: BDX)

Becton Dickinson & Co develops, manufactures, and sells a broad range of medical supplies, devices, laboratory equipment, and diagnostic products. The company operates in the medical technology industry, focusing on improving medication management, infection prevention, surgical and interventional procedures, drug delivery, anesthesiology care, infectious disease and cancer diagnosis, and cellular research. BD's solutions are designed to enhance patient safety and support healthcare institutions, physicians, life science researchers, clinical laboratories, the pharmaceutical industry, and the general public.

BD generates revenue through the sale of its diverse product portfolio, which includes peripheral intravenous catheters, advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care products, needle-free IV connectors, closed-system drug transfer devices, hazardous drug detection systems, conventional and safety hypodermic syringes, anesthesia needles, enteral syringes, sharps disposal systems, IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems, informatics and analytics solutions for enterprise medication management, pharmacy automation systems, prefillable drug delivery systems, advanced hemodynamic monitoring systems, automated blood culturing and tuberculosis culturing systems, microorganism identification and drug susceptibility systems, microbiology laboratory automation and informatics, dehydrated, liquid and plated media for clinical and microbiology applications, molecular testing systems for infectious diseases and women's health, rapid diagnostic assays for respiratory infections, fluorescence-activated cell sorters and analyzers, antibodies and kits for cell analysis, reagents for life science research, solutions for high-throughput single-cell gene and protein expression analysis, clinical oncology, immunological and transplantation diagnostic reagents, analyzers and informatics, blood collection systems, arterial blood gas devices, urine collection kits, molecular research tubes, capillary collection technologies, hernia and soft tissue repair products, biological grafts, bioresorbable grafts, biosurgery products, BD Surgiphor Antimicrobial Irrigation System, BD ChloraPrep surgical infection prevention products, percutaneous transluminal angioplasty balloon catheters, radio frequency ablation catheters, peripheral vascular stents, self-expanding and balloon-expandable stent grafts, vascular grafts, drug-coated balloons, ports, biopsy devices, chronic dialysis devices, inferior vena cava filters, endovascular fistula creation devices, drainage products, atherectomy and thrombectomy systems, urine management and measurement devices, indwelling, intermittent and external urine catheters, kidney stone management devices, Targeted Temperature Management devices, and fecal management devices. BD's primary customers include hospitals and clinics, physicians' office practices, consumers and retail pharmacies, governmental and nonprofit public health agencies, pharmaceutical companies, and healthcare workers.

• BD Medical: This segment produces a broad array of medical technologies and devices used to improve healthcare delivery. Key product lines include Medication Delivery Solutions, Medication Management Solutions, Pharmaceutical Systems, and Advanced Patient Monitoring. The segment serves hospitals and clinics, physicians' offices, consumers, retail pharmacies, governmental and nonprofit public health agencies, pharmaceutical companies, and healthcare workers.

• BD Life Sciences: This segment provides products for the safe collection and transport of diagnostic specimens, instruments, and reagent systems to detect a broad range of infectious diseases, healthcare-associated infections, and cancers. It also produces research and clinical tools for studying cells and their components. Key product lines include Diagnostic Solutions, Biosciences, and Specimen Management. The segment serves hospitals, laboratories and clinics, blood banks, healthcare workers, physicians' office practices, academic and government institutions, and pharmaceutical and biotechnology companies.

• BD Interventional: This segment provides vascular, urology, oncology, and surgical specialty products that are intended to be used once and then discarded or are either temporarily or permanently implanted. Key product lines include Surgery, Peripheral Intervention, and Urology and Critical Care. The segment serves hospitals, ambulatory surgery centers, individual healthcare professionals, extended care facilities, alternate site facilities, and patients via the Homecare business.

BD operates in the increasingly complex and challenging medical technology marketplace. The company competes with firms of varying sizes, some of which are more specialized or have greater financial resources. BD's competitive advantages include its focus on innovation, quality, service, reputation, distribution, and promotion. The company invests in research and development, quality management, quality improvement, product innovation, manufacturing, and supply chain to remain competitive and boost supply reliability and productivity.

BD's customers include a wide range of healthcare institutions, physicians, life science researchers, clinical laboratories, the pharmaceutical industry, and the general public. The company's products are used in various settings, including hospitals, clinics, physicians' offices, and retail pharmacies. BD's solutions are designed to meet the needs of healthcare providers and patients, supporting improved patient outcomes and operational efficiency.